

Table 19.31
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2007-2013

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
Lymphoid Neoplasm	79,125	70.9 (70.5 , 71.3)	90.6 (89.5 , 91.6)	80.2 (79.7 , 80.7)	60.5 (59.8 , 61.2)			
1 Hodgkin Lymphoma	6,722	87.4 (86.4 , 88.4)	97.0 (95.4 , 98.0)	91.5 (90.5 , 92.4)	56.8 (52.4 , 61.0)			
2 Non-Hodgkin lymphoma	70,440	69.8 (69.3 , 70.2)	88.7 (87.3 , 89.9)	78.5 (78.0 , 79.1)	61.2 (60.5 , 61.9)			
2(a) Non-Hodgkin lymphoma, B-cell	65,588	70.0 (69.5 , 70.5)	89.2 (87.8 , 90.5)	79.0 (78.4 , 79.6)	61.7 (60.9 , 62.4)			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	3,729	68.9 (67.2 , 70.6)	89.1 (87.5 , 90.5)	40.3 (36.8 , 43.9)	18.6 (13.8 , 23.9)			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	58,365	70.2 (69.6 , 70.7)	89.8 (85.9 , 92.7)	80.6 (80.0 , 81.2)	62.1 (61.3 , 62.9)			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	12,321	80.5 (79.3 , 81.7)	- (- , -)	88.9 (87.5 , 90.1)	75.9 (74.2 , 77.6)			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	11,170	82.7 (81.5 , 83.9)	- (- , -)	91.1 (89.7 , 92.3)	78.1 (76.3 , 79.8)			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	27	47.0 (24.9 , 66.4)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.1.3. Mantle-cell lymphoma	1,124	59.3 (55.2 , 63.2)	- (- , -)	68.9 (62.9 , 74.2)	53.6 (47.9 , 58.9)			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,213	82.9 (79.0 , 86.1)	- (- , -)	90.1 (85.8 , 93.2)	78.5 (72.9 , 83.1)			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	582	77.3 (71.5 , 82.0)	- (- , -)	86.0 (78.7 , 90.9)	72.0 (63.8 , 78.7)			
2(a) 2.2.2. Waldenstrom macroglobulinemia	631	87.6 (82.2 , 91.5)	- (- , -)	93.3 (87.6 , 96.5)	83.8 (75.6 , 89.5)			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	15,405	62.3 (61.3 , 63.3)	87.2 (81.2 , 91.4)	75.1 (73.8 , 76.3)	52.3 (50.8 , 53.7)			
2(a) 2.3.1. DLBCL, NOS ^c	15,151	61.9 (60.9 , 62.9)	88.1 (82.0 , 92.3)	74.6 (73.3 , 75.9)	52.3 (50.8 , 53.7)			
2(a) 2.3.2. Intravascular large B-cell lymphoma	33	61.3 (40.2 , 76.9)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.3. Primary effusion lymphoma	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	217	89.3 (83.6 , 93.2)	- (- , -)	91.3 (85.6 , 94.9)	- (- , -)			
2(a) 2.4. Burkitt lymphoma/leukemia	637	57.6 (53.2 , 61.8)	91.2 (84.2 , 95.2)	56.8 (50.8 , 62.4)	35.5 (27.8 , 43.2)			
2(a) 2.5. Marginal-zone lymphoma (MZL)	5,157	90.7 (89.1 , 92.1)	- (- , -)	94.7 (93.1 , 95.9)	87.3 (84.5 , 89.6)			
2(a) 2.5.1. Splenic MZL	455	82.7 (76.0 , 87.7)	- (- , -)	87.0 (78.6 , 92.3)	79.2 (68.5 , 86.6)			
2(a) 2.5.2. Extranodal MZL, MALT ^c type	3,212	94.9 (92.9 , 96.3)	- (- , -)	96.8 (95.1 , 97.9)	92.8 (88.8 , 95.4)			
2(a) 2.5.3. Nodal MZL	1,490	84.2 (80.9 , 86.9)	- (- , -)	91.4 (87.6 , 94.1)	78.8 (73.7 , 83.0)			
2(a) 2.6. Follicular lymphoma	8,993	88.3 (87.2 , 89.4)	- (- , -)	93.8 (92.8 , 94.7)	81.8 (79.6 , 83.7)			
2(a) 2.7. Hairy-cell leukemia	310	90.5 (82.9 , 94.8)	- (- , -)	97.3 (92.4 , 99.0)	75.8 (57.9 , 86.9)			
2(a) 2.8. Plasma cell neoplasms	14,319	49.4 (48.3 , 50.5)	- (- , -)	63.5 (61.9 , 65.1)	39.6 (38.0 , 41.1)			
2(a) 2.8.1. Plasmacytoma	755	67.6 (62.8 , 72.0)	- (- , -)	80.3 (74.3 , 85.1)	52.9 (45.5 , 59.8)			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	13,564	48.4 (47.2 , 49.5)	- (- , -)	62.4 (60.7 , 64.0)	38.9 (37.4 , 40.4)			
2(a) 2.9. Heavy chain disease	-	- (- , -)	- (- , -)	- (- , -)	- (- , -)			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	3,494	68.5 (66.2 , 70.7)	- (- , -)	80.0 (77.0 , 82.7)	62.4 (59.2 , 65.4)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.31 - continued
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2007-2013

Site	Count	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
		Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)		Percent (95% C.I.)	
2(b) Non-Hodgkin lymphoma, T-cell	4,348	67.0 (65.2 , 68.7)		85.2 (80.7 , 88.7)		73.8 (71.7 , 75.8)		52.0 (48.6 , 55.2)	
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	122	68.4 (59.0 , 76.1)		92.4 (80.9 , 97.1)		56.3 (41.9 , 68.4)		- (- , -)	
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	4,208	67.1 (65.2 , 68.8)		83.8 (78.5 , 87.9)		74.5 (72.3 , 76.4)		52.4 (49.0 , 55.7)	
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,133	92.6 (89.6 , 94.8)		93.2 (59.7 , 99.0)		95.3 (92.2 , 97.2)		87.6 (79.8 , 92.5)	
2(b) 2.1.1. Mycosis fungoides	1,103	93.9 (90.8 , 96.0)		93.2 (59.7 , 99.0)		96.1 (93.0 , 97.8)		89.7 (81.4 , 94.4)	
2(b) 2.1.2. Sezary syndrome	30	42.4 (21.4 , 62.0)		- (- , -)		- (- , -)		- (- , -)	
2(b) 2.2. Peripheral T-cell lymphoma	2,363	59.4 (57.0 , 61.7)		84.2 (74.4 , 90.5)		70.7 (67.7 , 73.5)		42.3 (38.3 , 46.4)	
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	798	37.7 (33.6 , 41.9)		- (- , -)		50.2 (44.3 , 55.8)		24.8 (19.1 , 30.9)	
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	338	45.9 (39.5 , 52.1)		- (- , -)		63.6 (54.0 , 71.7)		33.9 (25.7 , 42.2)	
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	44	90.5 (73.5 , 96.8)		- (- , -)		85.0 (63.1 , 94.4)		- (- , -)	
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	436	65.5 (60.1 , 70.4)		84.0 (70.0 , 91.8)		73.8 (67.3 , 79.3)		33.1 (22.5 , 44.2)	
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	-	- (- , -)		- (- , -)		- (- , -)		- (- , -)	
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	32	7.7 (0.7 , 26.3)		- (- , -)		- (- , -)		- (- , -)	
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	477	85.2 (80.1 , 89.1)		- (- , -)		89.9 (84.6 , 93.5)		77.2 (66.5 , 84.9)	
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	223	90.8 (82.3 , 95.4)		- (- , -)		95.2 (88.1 , 98.1)		79.4 (56.4 , 91.2)	
2(b) 2.3. Adult T-cell leukemia/lymphoma	429	56.0 (50.0 , 61.6)		82.1 (74.6 , 87.5)		40.6 (30.4 , 50.5)		23.9 (12.9 , 36.7)	
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	162	44.5 (34.8 , 53.7)		- (- , -)		48.8 (38.6 , 58.3)		37.1 (18.8 , 55.5)	
2(b) 2.5. T-cell large granular lymphocytic leukemia	47	74.8 (56.1 , 86.4)		- (- , -)		80.1 (58.5 , 91.3)		- (- , -)	
2(b) 2.6. Prolymphocytic leukemia, T-cell	74	13.3 (4.5 , 26.9)		- (- , -)		22.1 (8.8 , 39.2)		7.0 (0.5 , 26.4)	
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	-	- (- , -)		- (- , -)		- (- , -)		- (- , -)	
2(c) Non-Hodgkin lymphoma, unknown lineage	504	64.3 (59.2 , 68.9)		89.8 (82.3 , 94.3)		66.8 (57.8 , 74.4)		49.0 (41.5 , 56.2)	
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	196	69.6 (62.3 , 75.8)		90.6 (83.2 , 94.9)		53.7 (38.0 , 67.1)		19.3 (7.8 , 34.7)	
2(c) 2. Prolymphocytic leukemia, unknown lineage	-	- (- , -)		- (- , -)		- (- , -)		- (- , -)	
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	288	61.2 (54.2 , 67.4)		- (- , -)		73.9 (62.3 , 82.4)		54.1 (45.3 , 62.0)	
2(*) 1. Total precursor lymphoma/leukemia ^d	4,047	69.0 (67.4 , 70.6)		89.3 (87.8 , 90.6)		42.0 (38.6 , 45.2)		18.7 (14.3 , 23.6)	
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	63	62.1 (44.7 , 75.4)		- (- , -)		82.0 (58.0 , 93.0)		- (- , -)	
4 Lymphoid neoplasm, NOS ^c	1,900	51.9 (49.0 , 54.8)		86.4 (66.7 , 94.8)		70.5 (66.2 , 74.3)		41.4 (37.6 , 45.1)	

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.